Investing.com -- Shares of Mineralys Therapeutics (NASDAQ: MLYS ) surged 43% today following the announcement of positive topline results from its Launch-HTN and Advance-HTN trials of Lorundrostat, a treatment for uncontrolled and resistant hypertension. The stock’s ascent comes after a trading halt pending the news release, with investor sentiment bolstered once trading resumed.

The company’s press release dated March 10, 2025, detailed that both trials met their primary endpoints, with the lorundrostat 50 mg dose achieving a statistically significant reduction in systolic blood pressure. In the Launch-HTN trial, a 16.9 mmHg reduction was observed, along with a 9.1 mmHg placebo-adjusted reduction. The Advance-HTN trial saw a 7.9 mmHg placebo-adjusted reduction, assessed by a 24-hour ambulatory blood pressure monitoring at the end of treatment in week 12. These results suggest lorundrostat’s potential as a transformative therapy for millions of patients with hypertension in the United States.

Jon Congleton, CEO of Mineralys Therapeutics, expressed confidence in lorundrostat’s efficacy and safety profile, indicating the company’s belief in the drug’s regulatory approval prospects and significant commercial value. The full results from the Advance-HTN trial are scheduled to be presented on March 29, 2025, at the American College of Cardiology Scientific Sessions.

Safety and tolerability profiles from both trials were favorable, with a low incidence of serious adverse events and hyperkalemia. This data is expected to contribute to a positive benefit-risk profile for lorundrostat.

In addition to the upcoming detailed results presentation, Mineralys plans to share more data from these pivotal trials at future medical conferences and in peer-reviewed publications. The ongoing Transform-HTN open-label extension trial is set to provide further safety and efficacy data on lorundrostat.

This significant stock movement reflects investor optimism about the potential of lorundrostat to address a critical unmet medical need in the hypertension market. With cardiovascular diseases remaining a leading cause of death globally, treatments like lorundrostat could have a substantial impact on public health.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.